Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia

Blood

Volumn 114, Issue 6, 2009, Pages 1250-1253

  Greinacher, Andreas ^a   Fuerll, Birgitt ^a   Zinke, Heike ^a   Müllejans, Bernd ^b   Krüger, William ^c   Michetti, Noemi ^d   Motz, Wolfgang ^b   Schwertz, Hansjörg ^d  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b Klinikum Karlsburg   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; IMMUNOGLOBULIN G; THROMBOCYTE ANTIBODY; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; FIBRINOGEN RECEPTOR; PEPTIDE;

ACUTE CORONARY SYNDROME; AGED; ANAMNESIS; ARTICLE; BLOOD CULTURE; BONE MARROW EXAMINATION; CASE REPORT; CELL DIFFERENTIATION; CLINICAL FEATURE; CORONARY STENT; DRUG HALF LIFE; GASTROINTESTINAL HEMORRHAGE; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; SKIN BLEEDING; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; AUTOIMMUNE DISEASE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; IMMUNOLOGY; METHODOLOGY; THROMBOCYTOPOIESIS; TIME;

ACUTE CORONARY SYNDROME; AGED; AUTOANTIBODIES; AUTOIMMUNE DISEASES; GASTROINTESTINAL HEMORRHAGE; HUMANS; IMMUNOGLOBULIN G; MALE; MEGAKARYOCYTES; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; THROMBOCYTOPENIA; THROMBOPOIESIS; TIME FACTORS;

EID: 69849091506     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203034     Document Type: Article

References (15)

1. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis (RESTORE) Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
2. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
3. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention: IMPACT Investigators. Circulation. 1995;91:2151-2157.
4. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 2005;127:53S-59S.
5. Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost. 2006;4:678-679.
6. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation. 2001;104:870-875.
7. Coons JC, Barcelona RA, Freedy T, Hagerty MF. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother. 2005;39:368-372.
8. Langenscheidt F, Kiefel V, Santoso S, Nau A, Mueller-Eckhardt C. Quantitation of platelet antigens after chloroquine treatment. Eur J Haematol. 1989;42:186-192. (Pubitemid 19064949)
9. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70:1722-1726. (Pubitemid 18055614)
10. Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion. 2004;44:1033-1040. (Pubitemid 38823810)
11. Denis MM, Tolley ND, Bunting M, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell. 2005;122:379-391. (Pubitemid 41127140)
12. Schwertz H, Tolley ND, Foulks JM, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med. 2006;203:2433-2440. (Pubitemid 44664613)
13. Lonial S, Bilodeau PA, Langston AA, et al. Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature. Bone Marrow Transplant. 1999;24:1337-1341. (Pubitemid 30052790)
14. Tristano AG. Acquired amegakaryocytic thrombocytopenic purpura: review of a not very well-defined disorder. Eur J Intern Med. 2005;16:477-481.
15. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99:4-13.